Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
AstraZeneca
Information provided by (Responsible Party):
Grace McComsey, University Hospitals of Cleveland
ClinicalTrials.gov Identifier:
NCT01218802
First received: October 8, 2010
Last updated: March 12, 2014
Last verified: March 2014